The goal of this series is to provide osteopathic primary care clinicians, with evidence-based, multidisciplinary strategies to improve knowledge and competence of pain management with non-pharmacologic and non-opioid therapies and the methodology to safely integrate opioids into treatment regimens to mitigate risks of opioid use disorder while addressing current barriers to optimal management.

• State the role of both prescription and illicit opioids within osteopathic care.
• Discover the appropriate circumstances for prescribing full agonist opioids for chronic pain, guided by osteopathic philosophy.
• Analyze case studies to identify opportunities for using Buprenorphine and Methadone in the treatment of chronic pain or Opioid Use Disorder (OUD).
• Evaluate the skills in early detection of OUD by learning tools and techniques for assessment.
• Assess the risk/benefit profiles of starting, stopping, or modifying opioid prescriptions for pain management.
• Develop tailored treatment plans for patients with pain or OUD to include the significance of continuous management and support and incorporate a range of treatment options such as medication-assisted treatment, behavioral therapies, and support services.

There are 4 lectures contained within this Live Case Forum series, which will be released from April 2024 through November 2024.

• Live Case Forum - ACOFP (April 4, 2024): ACOFP 2024 Annual Convention and Scientific Seminars
• Live Case Forum 1 (June 12, 2024): Live Virtual/Webcast
• Live Case Forum 2 (August 13, 2024): Live Virtual/Webcast
• In-person (September 20 - 22): OMED, San Antonio, TX
• Live Case Forum - ACOI (November 1, 2024): ACOI 2024 Annual Convention and Scientific Sessions

Disclosure Statements

ACOFP and ACOI are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of an ineligible company. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACOFP and ACOI require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company (those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients). Individuals in a position to control the content may include, but are not limited to, planning committee members, authors, faculty, speakers, reviewers, and activity staff. ACOFP and ACOI review all disclosed relationships to determine which are relevant and then work with the applicable contributors to mitigate the relevant financial relationships. No relevant financial relationships were identified for any individual in control of content for this specific activity series. 

CME Credit and Designation Statements 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Osteopathic Family Physicians (ACOFP) and American College of Osteopathic Internists (ACOI). ACOFP is accredited by the ACCME to provide continuing medical education for physicians. ACOFP designates this enduring activity series for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the activity. ACOFP is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. ACOFP designates this enduring activity series for a maximum of 1.5 AOA Category 1-A credits and will report continuing medical education (CME) credits commensurate with the physician’s participation in this program. 

Support Acknowledgement 

The activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. 

Disclaimer

ACOFP and ACOI present this information for educational purposes only. The content is provided solely by individuals who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. ACOFP, ACOI, and the supporter assume no liability for the information herein.

DEA MATE Requirements

As an accredited organization named in section 1263 of CAA 2023, ACOFP and ACOI have developed this series that may satisfy all or portions of your DEA training requirements.

The goal of this series is to provide osteopathic primary care clinicians, with evidence-based, multidisciplinary strategies to improve knowledge and competence of pain management with non-pharmacologic and non-opioid therapies and the methodology to safely integrate opioids into treatment regimens to mitigate risks of opioid use disorder while addressing current barriers to optimal management.

• State the role of both prescription and illicit opioids within osteopathic care.
• Discover the appropriate circumstances for prescribing full agonist opioids for chronic pain, guided by osteopathic philosophy.
• Analyze case studies to identify opportunities for using Buprenorphine and Methadone in the treatment of chronic pain or Opioid Use Disorder (OUD).
• Evaluate the skills in early detection of OUD by learning tools and techniques for assessment.
• Assess the risk/benefit profiles of starting, stopping, or modifying opioid prescriptions for pain management.
• Develop tailored treatment plans for patients with pain or OUD to include the significance of continuous management and support and incorporate a range of treatment options such as medication-assisted treatment, behavioral therapies, and support services.

There are 4 lectures contained within this Live Case Forum series, which will be released from April 2024 through November 2024.

• Live Case Forum - ACOFP (April 4, 2024): ACOFP 2024 Annual Convention and Scientific Seminars
• Live Case Forum 1 (June 12, 2024): Live Virtual/Webcast
• Live Case Forum 2 (August 13, 2024): Live Virtual/Webcast
• In-person (September 20 - 22): OMED, San Antonio, TX
• Live Case Forum - ACOI (November 1, 2024): ACOI 2024 Annual Convention and Scientific Sessions

Disclosure Statements

ACOFP and ACOI are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of an ineligible company. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACOFP and ACOI require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company (those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients). Individuals in a position to control the content may include, but are not limited to, planning committee members, authors, faculty, speakers, reviewers, and activity staff. ACOFP and ACOI review all disclosed relationships to determine which are relevant and then work with the applicable contributors to mitigate the relevant financial relationships. No relevant financial relationships were identified for any individual in control of content for this specific activity series. 

CME Credit and Designation Statements 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Osteopathic Family Physicians (ACOFP) and American College of Osteopathic Internists (ACOI). ACOFP is accredited by the ACCME to provide continuing medical education for physicians. ACOFP designates this enduring activity series for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the activity. ACOFP is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. ACOFP designates this enduring activity series for a maximum of 6.0 AOA Category 1-A credits and will report continuing medical education (CME) credits commensurate with the physician’s participation in this program. 

Support Acknowledgement 

The activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. 

Disclaimer

ACOFP and ACOI present this information for educational purposes only. The content is provided solely by individuals who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. ACOFP, ACOI, and the supporter assume no liability for the information herein.

DEA MATE Requirements

As an accredited organization named in section 1263 of CAA 2023, ACOFP and ACOI have developed this series that may satisfy all or portions of your DEA training requirements.

The goal of this series is to provide osteopathic primary care clinicians, with evidence-based, multidisciplinary strategies to improve knowledge and competence of pain management with non-pharmacologic and non-opioid therapies and the methodology to safely integrate opioids into treatment regimens to mitigate risks of opioid use disorder while addressing current barriers to optimal management.

• State the role of both prescription and illicit opioids within osteopathic care.
• Discover the appropriate circumstances for prescribing full agonist opioids for chronic pain, guided by osteopathic philosophy.
• Analyze case studies to identify opportunities for using Buprenorphine and Methadone in the treatment of chronic pain or Opioid Use Disorder (OUD).
• Evaluate the skills in early detection of OUD by learning tools and techniques for assessment.
• Assess the risk/benefit profiles of starting, stopping, or modifying opioid prescriptions for pain management.
• Develop tailored treatment plans for patients with pain or OUD to include the significance of continuous management and support and incorporate a range of treatment options such as medication-assisted treatment, behavioral therapies, and support services.

There are 4 lectures contained within this Live Case Forum series, which will be released from April 2024 through November 2024.

• Live Case Forum - ACOFP (April 4, 2024): ACOFP 2024 Annual Convention and Scientific Seminars
• Live Case Forum 1 (June 12, 2024): Live Virtual/Webcast
• Live Case Forum 2 (August 13, 2024): Live Virtual/Webcast
• In-person (September 20 - 22): OMED, San Antonio, TX
• Live Case Forum - ACOI (November 1, 2024): ACOI 2024 Annual Convention and Scientific Sessions

Disclosure Statements

ACOFP and ACOI are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of an ineligible company. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACOFP and ACOI require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company (those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients). Individuals in a position to control the content may include, but are not limited to, planning committee members, authors, faculty, speakers, reviewers, and activity staff. ACOFP and ACOI review all disclosed relationships to determine which are relevant and then work with the applicable contributors to mitigate the relevant financial relationships. No relevant financial relationships were identified for any individual in control of content for this specific activity series. 

CME Credit and Designation Statements 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Osteopathic Family Physicians (ACOFP) and American College of Osteopathic Internists (ACOI). ACOFP is accredited by the ACCME to provide continuing medical education for physicians. ACOFP designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the activity. ACOFP is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. ACOFP designates this enduring activity for a maximum of 1.5 AOA Category 1-A credits and will report continuing medical education (CME) credits commensurate with the physician’s participation in this program. 

Support Acknowledgement 

The activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. 

Disclaimer

ACOFP and ACOI present this information for educational purposes only. The content is provided solely by individuals who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. ACOFP, ACOI, and the supporter assume no liability for the information herein.

DEA MATE Requirements

As an accredited organization named in section 1263 of CAA 2023, ACOFP and ACOI have developed this series that may satisfy all or portions of your DEA training requirements.

The goal of this series is to provide osteopathic primary care clinicians, with evidence-based, multidisciplinary strategies to improve knowledge and competence of pain management with non-pharmacologic and non-opioid therapies and the methodology to safely integrate opioids into treatment regimens to mitigate risks of opioid use disorder while addressing current barriers to optimal management.

• State the role of both prescription and illicit opioids within osteopathic care.
• Discover the appropriate circumstances for prescribing full agonist opioids for chronic pain, guided by osteopathic philosophy.
• Analyze case studies to identify opportunities for using Buprenorphine and Methadone in the treatment of chronic pain or Opioid Use Disorder (OUD).
• Evaluate the skills in early detection of OUD by learning tools and techniques for assessment.
• Assess the risk/benefit profiles of starting, stopping, or modifying opioid prescriptions for pain management.
• Develop tailored treatment plans for patients with pain or OUD to include the significance of continuous management and support and incorporate a range of treatment options such as medication-assisted treatment, behavioral therapies, and support services.

There are 4 lectures contained within this Live Case Forum series, which will be released from April 2024 through November 2024.

• Live Case Forum - ACOFP (April 4, 2024): ACOFP 2024 Annual Convention and Scientific Seminars
• Live Case Forum 1 (June 12, 2024): Live Virtual/Webcast
• Live Case Forum 2 (August 13, 2024): Live Virtual/Webcast
• In-person (September 20 - 22): OMED, San Antonio, TX
• Live Case Forum - ACOI (November 1, 2024): ACOI 2024 Annual Convention and Scientific Sessions

Disclosure Statements

ACOFP and ACOI are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of an ineligible company. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACOFP and ACOI require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company (those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients). Individuals in a position to control the content may include, but are not limited to, planning committee members, authors, faculty, speakers, reviewers, and activity staff. ACOFP and ACOI review all disclosed relationships to determine which are relevant and then work with the applicable contributors to mitigate the relevant financial relationships. No relevant financial relationships were identified for any individual in control of content for this specific activity series. 

CME Credit and Designation Statements 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Osteopathic Family Physicians (ACOFP) and American College of Osteopathic Internists (ACOI). ACOFP is accredited by the ACCME to provide continuing medical education for physicians. ACOFP designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the activity. ACOFP is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. ACOFP designates this enduring activity for a maximum of 1.5 AOA Category 1-A credits and will report continuing medical education (CME) credits commensurate with the physician’s participation in this program. 

Support Acknowledgement 

The activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. 

Disclaimer

ACOFP and ACOI present this information for educational purposes only. The content is provided solely by individuals who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. ACOFP, ACOI, and the supporter assume no liability for the information herein.

DEA MATE Requirements

As an accredited organization named in section 1263 of CAA 2023, ACOFP and ACOI have developed this series that may satisfy all or portions of your DEA training requirements.

2024 Clinical Challenges in Hospital Medicine (On-Demand)

The ACOI 2024 Clinical Challenges in Hospital Medicine offers the latest updates and tips for hospital-based internists and subspecialists to manage care in the inpatient setting.

CME Credit Available:

This activity offers a total of 26 hours of AOA Category 1A credits and AMA PRA Category 1 Credits™.

Note: ACOI reports credits to the AOA after the end of each quarter. 

Learning Objectives:

• Learn new treatments for diabetes and CKM syndrome.
  
• Get updates on obesity management.
• Summarize the latest guideline strategies for blood and blood product transfusions.
• Discuss renal failure in the intensive care setting.
• Review the latest updates in GI therapies.
• Identify new approaches to acutely ill patients on chronic immunosuppressive medicine.
• Review updates to hospital isolation guidelines.
• Review updates on care of the transgender patient.
• Learn new billing code updates.
• Review best practices in the management of hospital delirium and agitation.
• Learn updates on meeting hospital goal metrics.

Release & Review Date: 

This activity is valid from July 31, 2024, until July 31, 2027.

2024 Internal Medicine Comprehensive Update (On-Demand)

The ACOI 2024 Internal Medicine Comprehensive Update will help you to maintain best-practice knowledge and skills in all areas of practice of internal medicine and subspecialty topics.

CME Credit Available:

This activity offers a total of 37.25 hours of AOA Category 1A credits and AMA PRA Category 1 Credits™.

Note: ACOI reports credits to the AOA after the end of each quarter. 

Learning Objectives:

• Revise and refresh knowledge of core topics in internal medicine and the subspecialties through discussion of common and uncommon clinical problems.
  
• Apply successful strategies to respond to challenging scenarios.
• Synthesize and implement changes in clinical practice in accordance with recent advances, guidelines, and evidence-based practice.

Release & Review Date: 

  This activity is valid from July 31, 2024, until July 31, 2027.

CME Credit Available: 

This activity offers .75 1A AOA

Note: ACOI reports credits to the AOA after the end of each quarter.  

Learning Objectives:

Those participating in this activity will receive information that should allow them to: 

• The differences for split shared visits in 2024.
• Physician rules for supervision in 2024.
• The new Hospital and Observation Services codes and guidelines.

Conflict of Interest Disclosures:

ACOI requires each planner and presenter to identify all conflicts of interest and mitigate risk of bias using a series of strategies for relevant conflicts. Unless otherwise noted below, the ACOI, ACOI staff and planners for this activity have no relevant financial relationships with ineligible companies to disclose.

Jill M. Young, CPC, CEDC, CIMC, faculty for this activity, has no relevant relationships with ineligible companies to disclose.  

Release & Review Date:

This activity is valid from July 31, 2024, until July 31, 2027.

CME Credit Available: 

This activity offers .75 1A AOA

Note: ACOI reports credits to the AOA after the end of each quarter.  

Learning Objectives:

Those participating in this activity will receive information that should allow them to: 

• Scripting options to counsel patients/families facing serious illness.
• What assistance is available to have difficult conversations.
• Preemptive and management strategies for each conversation.

Conflict of Interest Disclosures:

ACOI requires each planner and presenter to identify all conflicts of interest and mitigate risk of bias using a series of strategies for relevant conflicts. Unless otherwise noted below, the ACOI, ACOI staff and planners for this activity have no relevant financial relationships with ineligible companies to disclose.

Annette T. Carron, DO, MACOI, faculty for this activity, has no relevant relationships with ineligible companies to disclose.  

Release & Review Date:

This activity is valid from July 31, 2024, until July 31, 2027.

CME Credit Available: 

This activity offers .75 1A AOA

Note: ACOI reports credits to the AOA after the end of each quarter.  

Learning Objectives:

Those participating in this activity will receive information that should allow them to: 

• The key challenges and factors influencing the transition from inpatient to outpatient management in chronic pain patients.
• Best practices for developing personalized care plans to facilitate seamless transitions and improve patient outcomes.
• Challenges associated with transitions and solutions to overcome barriers for more effective chronic pain management.

Conflict of Interest Disclosures:

ACOI requires each planner and presenter to identify all conflicts of interest and mitigate risk of bias using a series of strategies for relevant conflicts. Unless otherwise noted below, the ACOI, ACOI staff and planners for this activity have no relevant financial relationships with ineligible companies to disclose.

Jean Storm, DO, faculty for this activity, has no relevant relationships with ineligible companies to disclose.  

Release & Review Date:

This activity is valid from July 31, 2024, until July 31, 2027.

CME Credit Available: 

This activity offers .75 1A AOA

Note: ACOI reports credits to the AOA after the end of each quarter.  

Learning Objectives:

Those participating in this activity will receive information that should allow them to: 

• The metrics commonly used in an acute care setting.
• The importance of these metrics to a hospital provider, and how they can impact them.
• The financial metrics important to the C-suite and hospital finance/revenue cycle teams.

Conflict of Interest Disclosures:

ACOI requires each planner and presenter to identify all conflicts of interest and mitigate risk of bias using a series of strategies for relevant conflicts. Unless otherwise noted below, the ACOI, ACOI staff and planners for this activity have no relevant financial relationships with ineligible companies to disclose.

Ariana L. Peters, DO, FACOI, faculty for this activity, has no relevant relationships with ineligible companies to disclose.  

Release & Review Date:

This activity is valid from July 31, 2024, until July 31, 2027.